Top

Published in:

01-01-2013 | Gastrointestinal Oncology

Aldehyde Dehydrogenase 1 Expression is Associated with Poor Prognosis in Patients with Esophageal Squamous Cell Carcinoma

Authors: Takuya Minato, MD, Yota Yamamoto, MD, PhD, Junici Seike, MD, PhD, Takahiro Yoshida, MD, PhD, Hiromichi Yamai, MD, PhD, Hirokazu Takechi, MD, Yasuhiro Yuasa, MD, PhD, Yoshihito Furukita, MD, Masakazu Goto, MD, Yoshimi Bando, MD, PhD, Akira Tangoku, MD, PhD

Published in: Annals of Surgical Oncology | Issue 1/2013

Background

Aldehyde dehydrogenase 1 (ALDH1) and CD44 act as important biomarkers in several solid tumors. However, few studies have examined the relationships between ALDH1 expression and the prognosis and clinical characteristics of esophageal squamous cell carcinoma (ESCC).

Methods

This study was a retrospective case–control study and included 152 patients with ESCC. A total of 56 patients underwent surgery (OP group), 40 patients received neoadjuvant chemotherapy involving weekly docetaxel plus 5-fluorouracil and low-dose cisplatin (DFP therapy) prior to undergoing surgery (NAC group), and 56 patients received initial systemic DFP therapy (CT group). The ALDH1 and CD44 immunohistochemical expression levels of each tumor were evaluated and compared with the prognosis and clinical characteristics of the ESCC patients.

Results

In the OP and NAC groups, multivariate analysis found that ALDH1 was independently associated with postoperative recurrence and prognosis (OP group, P = 0.004 and 0.016, respectively; NAC group, P = 0.026 and 0.014, respectively). In addition, CD44 was found to be associated with postoperative recurrence in the OP group and prognosis in the NAC group (P = 0.024 and 0.047, respectively). Among the ALDH1-negative clinical stage II/III patients, the OP and NAC groups displayed better prognoses than the CT group (P < 0.001). However, among the ALDH1-positive clinical stage II/III patients, the OP and NAC groups displayed poorer prognoses than the CT group (P = 0.049).

Conclusions

ALDH1 was found to be a predictor of postoperative recurrence and prognosis in ESCC, and CD44 might be a predictor of recurrence and prognosis. ALDH1 expression might affect the treatment strategy for ESCC.

Pisani P, Parkin DM, Ferlay J. Estimates of the worldwide mortality from eighteen major cancer in 1985. Implications for prevention and projections of future burden. Int J Cancer. 1993;55:891–903.

Ando N, Ozawa S, Kitagawa Y, Shinozawa Y, Kitajima M. Improvement in the results of surgical treatment of advanced squamous esophageal carcinoma during 15 consecutive years. Ann Surg. 2000;232:225–32.PubMedCrossRef

Gebski V, Burmeister B, Smithers BM, Foo K, Zalcberg J, Simes J. Survival benefits from neoadjuvant chemoradiotherapy or chemotherapy in oesophageal carcinoma: a meta-analysis. Lancet Oncol. 2007;8:226–34.PubMedCrossRef

Ando N, Iizuka T, Ide H, Ishida K, Shinoda M, Nishimaki T, et al. Surgery plus chemotherapy compared with surgery alone for localized squamous cell carcinoma of the thoracic esophagus: a Japan Clinical Oncology Group Study—JCOG9204. J Clin Oncol. 2003;21:4592–6.PubMedCrossRef

Ando N, Kato H, Igaki H, Shinoda M, Ozawa S, Shimizu H, et al. A randomized trial comparing postoperative adjuvant chemotherapy with cisplatin and 5-fluorouracil versus preoperative chemotherapy for localized advanced squamous cell carcinoma of the thoracic esophagus (JCOG 9907). Ann Surg Oncol. 2012;19:68–74.PubMedCrossRef

Gotoda T, Matsumura Y, Kondo H, Ono H, Kanamoto A, Kato H, et al. Expression of CD44 variants and prognosis in oesophageal squamous cell carcinoma. Gut. 2000;46:14–9.PubMedCrossRef

Li DM, Li SS, Zhang YH, Zhang HJ, Gao DL, Wang YX. Expression of human chorionic gonadotropin, CD44v6 and CD44v4/5 in esophageal squamous cell carcinoma. World J Gastroenterol. 2005;11:7401–4.PubMed

Yamamoto Y, Yamai H, Seike J, Yoshida T, Takechi H, Furukita Y, et al. Prognosis of esophageal squamous cell carcinoma in patients positive for human epidermal growth factor receptor family can be improved by initial chemotherapy with docetaxel, fluorouracil, and cisplatin. Ann Surg Oncol. 2012;19:757–65.PubMedCrossRef

Ma I, Allan AL. The role of human aldehyde dehydrogenase in normal and cancer stem cells. Stem Cell Rev. 2011;7:292–306.PubMedCrossRef

10.

Marchitti SA, Brocker C, Stagos D, Vasiliou V. Non-P450 aldehyde oxidizing enzymes: the aldehyde dehydrogenase superfamily. Expert Opin Drug Metab Toxicol. 2008;4:697–720.PubMedCrossRef

11.

Ross SA, McCaffery PJ, Drager UC, De Luca LM. Retinoids in embryonal development. Physiol Rev. 2000;80:1021–54.PubMed

12.

Lassen N, Bateman JB, Estey T, Kuszak JR, Nees DW, Piatigorsky J, et al. Multiple and additive functions of ALDH3A1 and ALDH1A1: cataract phenotype and ocular oxidative damage in Aldh3a1(−/−)/Aldh1a1(−/−) knock-out mice. J Biol Chem. 2007;282:25668–76.PubMedCrossRef

13.

Moreb JS, Mohuczy D, Ostmark B, Zucali JR. RNAi-mediated knockdown of aldehyde dehydrogenase class-1A1 and class-3A1 is specific and reveals that each contributes equally to the resistance against 4-hydroperoxycyclophosphamide. Cancer Chemother Pharmacol. 2007;59:127–36.PubMedCrossRef

14.

Tanei T, Morimoto K, Shimazu K, Kim SJ, Tanji Y, Taguchi T, et al. Association of breast cancer stem cell identified by aldehyde dehydrogenase 1 expression with resistance to sequential Paclitaxel and epirubicin-based chemotherapy for breast cancers. Clin Cancer Res. 2009;15:4234–41.PubMedCrossRef

15.

Ginestier C, Hur MH, Charafe-Jauffret E, Monville F, Dutcher J, Brown M, et al. ALDH1 is a marker of normal and malignant human mammary stem cells and a predictor of poor clinical outcome. Cell Stem Cell. 2007;1:555–67.PubMedCrossRef

16.

Rasheed ZA, Yang J, Wang Q, Kowalski J, Freed I, Murter C, et al. Prognostic significance of tumorgenic cells with mesenchymal features in pancreatic adenocarcinoma. J Natl Cancer Inst. 2010;102:340–51.PubMedCrossRef

17.

Li T, Su Y, Mei Y, Leng Q, Leng B, Liu Z, et al. ALDH1 is a marker for malignant prostate stem cells and predictor of prostate cancer patients outcome. Lab Invest. 2010;90:234–44.PubMedCrossRef

18.

Silva IA, Bai S, McLean K, Griffith K, Thomas D, Ginestier C, et al. Aldehyde dehydrogenase and CD133 define angiogenic ovarian cancer stem cells that portend poor patient survival. Cancer Res. 2011;71:3991–4001.PubMedCrossRef

19.

Croker AK, Allan AL. Inhibition of aldehyde dehydrogenase (ALDH) activity reduces chemotherapy and radiation resistance of stem-like ALDHhiCD44+ human breast cancer cells. Breast Cancer Res Treat. 2012;133:75–87.PubMedCrossRef

20.

Richardson ME, Siemann DW. Tumor cell heterogeneity: impact on mechanisms of therapeutic drug resistance. Int J Radiat Oncol Biol Phys. 1997;39:789–95.PubMedCrossRef

21.

Goldstein LA, Zhou DF, Picker LJ, Minty CN, Bargatze RF, Ding JF, et al. A human lymphocyte homing receptor, the hermes antigen, is related to cartilage proteoglycan core and link proteins. Cell. 1989;56:1063–72.PubMedCrossRef

22.

Rudzki Z, Jothy S. CD44 and the adhesion of neoplastic cells. Mol Pathol. 1997;50:57–71.PubMedCrossRef

23.

de los Toyos J, Jalkanen S, Butcher EC. Flow cytometric analysis of the Hermes homing-associated antigen on human lymphocyte subsets. Blood. 1989;74:751–60.PubMed

24.

Aruffo A, Stamenkovic I, Melnick M, Underhill CB, Seed B. CD44 is the principal cell surface receptor for hyaluronate. Cell. 1990;61:1303–13.PubMedCrossRef

25.

Arch R, Wirth K, Hofmann M, Ponta H, Matzku S, Herrlich P, et al. Participation in normal immune responses of a metastasis-inducing splice variant of CD44. Science. 1992;257:682–5.PubMedCrossRef

26.

Tanabe KK, Stamenkovic I, Cutler M, Takahashi K. Restoration of CD44H expression in colon carcinomas reduces tumorigenicity. Ann Surg. 1995;222:493–501, (discussion 501–3).PubMed

27.

Wielenga VJ, Heider KH, Offerhaus GJ, Adolf GR, van den Berg FM, Ponta H, et al. Expression of CD44 variant proteins in human colorectal cancer is related to tumor progression. Cancer Res. 1993;53:4754–6.PubMed

28.

Heider KH, Dämmrich J, Skroch-Angel P, Müller-Hermelink HK, Vollmers HP, Herrlich P, et al. Differential expression of CD44 splice variants in intestinal- and diffuse-type human gastric carcinomas and normal gastric mucosa. Cancer Res. 1993;53:4197–203.PubMed

29.

The Japan Esophageal Society. Guidelines for the Clinical and Pathologic Studies on Carcinoma of the Esophagus. 10th ed. Tokyo: Kanehara; 2008.

30.

Eisenhauer EA, Therasse P, Bogaerts J, Schwartz LH, Sargent D, Ford R, et al. New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). Eur J Cancer. 2009;45:228–47.PubMedCrossRef

31.

Yokota T, Hatooka S, Ura T, Abe T, Takahari D, Shitara K, et al. Docetaxel plus 5-fluorouracil and cisplatin (DCF) induction chemotherapy for locally advanced borderline-resectable T4 esophageal cancer. Anticancer Res. 2011;31: 3535–41.PubMed

32.

Yamasaki M, Miyata H, Tanaka K, Shiraishi O, Motoori M, Peng YF, et al. Multicenter phase I/II study of docetaxel, cisplatin and fluorouracil combination chemotherapy in patients with advanced or recurrent squamous cell carcinoma of the esophagus. Oncology. 2011;80:307–13.PubMedCrossRef

33.

Yoshida T, Seike J, Miyoshi T, Yamai H, Takechi H, Yuasa Y, et al. Preoperative chemotherapy with weekly docetaxel plus low-dose cisplatin and 5-fluorouracil for stage II/III squamous cell carcinoma of the esophagus. Esophagus. 2010;7:95–100.CrossRef

34.

Ueshima Y, Matsuda Y, Tsutsumi M, Takada A. Role of the aldehyde dehydrogenase-1 isozyme in the metabolism of acetaldehyde. Alcohol Alcohol Suppl. 1993;1B:15–9.PubMed

Title: Aldehyde Dehydrogenase 1 Expression is Associated with Poor Prognosis in Patients with Esophageal Squamous Cell Carcinoma
Authors: Takuya Minato, MD
Yota Yamamoto, MD, PhD
Junici Seike, MD, PhD
Takahiro Yoshida, MD, PhD
Hiromichi Yamai, MD, PhD
Hirokazu Takechi, MD
Yasuhiro Yuasa, MD, PhD
Yoshihito Furukita, MD
Masakazu Goto, MD
Yoshimi Bando, MD, PhD
Akira Tangoku, MD, PhD
Publication date: 01-01-2013
Publisher: Springer-Verlag
Published in: Annals of Surgical Oncology / Issue 1/2013
Print ISSN: 1068-9265
Electronic ISSN: 1534-4681
DOI: https://doi.org/10.1245/s10434-012-2535-8

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Aldehyde Dehydrogenase 1 Expression is Associated with Poor Prognosis in Patients with Esophageal Squamous Cell Carcinoma

Background

Methods

Results

Conclusions

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Background

Methods

Results

Conclusions

Please log in to get access to this content

Other articles of this Issue 1/2013

Comparison of the Sixth and the Seventh Editions of the UICC Classification for Perihilar Cholangiocarcinoma

Is Restaging with Chest and Abdominal CT Scan after Neoadjuvant Chemoradiotherapy for Locally Advanced Rectal Cancer Necessary?

Cost-Effectiveness of Treatment Strategies for Primary Operable Pancreatic Head Adenocarcinoma: Do We Have More Scientific Evidence to Call for Further Centralization of Care?

Detailed Pathologic Characteristics of the Primary Colorectal Tumor Independently Predict Outcome after Hepatectomy for Metastases

Definition of Patients Presenting a High Risk of Developing Peritoneal Carcinomatosis After Curative Surgery for Colorectal Cancer: A Systematic Review

Hepatic Pedicle Clamping During Hepatic Resection for Colorectal Liver Metastases: No Impact on Survival or Hepatic Recurrence